Sitemap

• Alliance Partners
• Homepage
• Clinical Trials
• Disease Areas
  • Acute Myeloid Leukemia
  • Beta-thalassemia
  • Breast Cancer
  • Lung Cancer
  • Lymphoma
  • Myelodysplastic Syndromes
  • Multiple Myeloma
  • Pancreatic Cancer
• Molecules
  • AG-881 (Pan-IDH Inhibitor)
  • Azacitidine (DNA Methyltransferase Inhibitor)
  • bb2121 (Anti-BCMA CAR T)
  • CC-122 (Cereblon Targeting Agent)
  • CC-486 (DNA Methyltransferase Inhibitor)
  • CC-90002 (Anti-CD47 Antibody)
  • Durvalumab (PD-L1 Inhibitor)
  • Enasidenib (IDH2 Inhibitor)
  • Lenalidomide (IMiD® Agent)
  • Luspatercept (Erythroid Maturation Agent)
  • Lisocabtagene Maraleucel (Liso-Cel; JCAR017; Anti-CD19 CAR T Cells)
  • Marizomib (Proteasome Inhibitor)
  • nab-Paclitaxel (Albumin-Bound Microtubule Inhibitor)
  • OMP-305B83 (Anti-DLL4/VEGF Bispecific Antibody)
  • Pomalidomide (IMiD® Agent)
  • Romidepsin (Histone Deacetylase Inhibitor)
  • Tislelizumab (BGB-A317; Anti–PD-1 Monoclonal Antibody)
• Pathways
  • Immuno-Oncology
    • Activity of IMiD® Agents
    • Combining Hypomethylating and Immuno-Oncology Agents
    • Combining Chemotherapy and Immuno-Oncology Agents
    • Checkpoint Inhibition (PD-1/PD-L1)
    • Macrophage Activation (CD47)
    • B-Cell Maturation Antigen (BCMA)
    • B-Cell Differentiation (CD19)
    • Chimeric Antigen Receptor (CAR) T Cells
    • Inducible T-Cell Costimulator (ICOS)
  • Epigenetics
    • DNA Methylation
    • Histone Modification
    • Isocitrate Dehydrogenase (IDH) Mutations
    • Bromodomain and Extra-Terminal Motif (BET) Proteins
    • Lysine-Specific Histone Demethylase 1 (LSD1)
  • Protein Homeostasis
    • Cereblon/E3 Ligase Pathway
    • Pleiotropic Pathway Modification
    • Proteasome Pathway
    • Deubiquitinating Enzymes
  • Biotherapeutics and Novel Targets
    • Notch Signaling
    • Aberrant Smad2/3 Signaling
    • Albumin Mediated Delivery (nab Technology)
    • Cell Signaling
• Pipeline
• Research Partners
• Resources
  • Celgene Medical Information
  • Contact